FDA

FDA Accepts Teva Pharma’s BLA for Migraine Drug

After running through what was a volatile past week, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) seems to be settling down — at least a little. The Israeli pharma giant kicked ...
Read Full Story »

Pfizer Headed for New High After FDA Nod for Joint Disease Treatment

Shares of Pfizer Inc. (NYSE: PFE) rose about 1.3% in afterhours trading Thursday after the company announced that the U.S. Food and Drug Administration (FDA) had approved Xeljanz (tofacitinib) for ...
Read Full Story »

Will Consumers Trust Generic Viagra?

If there is one drug from pharmaceutical giants that may have changed the world in lifestyle, Viagra might be the first one that comes to mind. It has helped millions ...
Read Full Story »

Is This the Turnaround SteadyMed Has Waited For?

SteadyMed Ltd. (NASDAQ: STDY) shares made an incredibly gain to close out the week, after a positive meeting with the U.S. Food and Drug Administration (FDA). Specifically, the firm said ...
Read Full Story »

Acorda Therapeutics Gets Crushed After Halting Parkinson’s Trial

Acorda Therapeutics Inc. (NASDAQ: ACOR) saw its shares drop sharply following an update on its Parkinson’s trial. The company paused new enrollment in the long-term safety studies, pending further discussion ...
Read Full Story »

Why Otonomy Shares Are Skyrocketing

Otonomy Inc. (NASDAQ: OTIC) reported its most recent quarterly results after the markets closed on Wednesday and gave an update on its late-stage trial in patients with Ménière’s disease. Although ...
Read Full Story »

Keryx Biopharmaceuticals FDA Win Outweighed by Q3 Loss

Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) shares took a big step back on Tuesday after the company announced its third-quarter results and an update from the U.S. Food and Drug Administration ...
Read Full Story »

Can This FDA Approval Keep Lifting Geron?

Geron Corp. (NASDAQ: GERN) is one of the few biopharma winners on Tuesday, with the health care sector in general pushing slightly lower on the day. The reason for Geron's ...
Read Full Story »

Top Biopharma Events Coming by the End of 2017

As the markets continue to hit all-time highs, biotech and pharmaceutical companies have been part of these massive gains. There is a very positive sentiment in the health care sector ...
Read Full Story »

Does Gilead’s CAR T Approval Vindicate the High Acquisition Price for Kite Pharma?

Gilead Sciences Inc. (NASDAQ: GILD) has seen many analysts raise their price targets in recent weeks, and now there is a new U.S. Food and Drug Administration (FDA) approval that ...
Read Full Story »

Even More Biopharma and FDA Catalysts Coming in October

As the markets continue to hit all-time highs, biotech and pharmaceutical companies have been part of these massive gains. There is a very positive sentiment in the health care sector ...
Read Full Story »

FDA Update Keeps Rigel Pharmaceuticals Above Water

Shares of Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) saw a solid gain to start off the week after the company gave an update from its meeting with the U.S. Food and ...
Read Full Story »

Major Biotech, Pharma and FDA Catalysts Coming in October

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a ...
Read Full Story »

The List of Failed Alzheimer’s Drug Treatments Keeps Growing

If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's ...
Read Full Story »

FDA Crashes Down on Intercept’s Deadly Drug

Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) shares tumbled on Thursday after it came to light that the U.S. Food and Drug Administration (FDA) had issued a warning about the firm’s liver ...
Read Full Story »